Report Regina Elena2002corr
Total Page:16
File Type:pdf, Size:1020Kb
ISTITUTO NAZIONALE TUMORI “REGINA ELENA” • Roma “REGINA ELENA”NATIONAL CANCER INSTITUTE • Rome SCIENTIFIC2004 REPORT Codice Anagrafe Ricerca: L123003Z I E ISTITUTOR NAZIONALE TUMORI REGINA ELENA ISTITUTO NAZIONALE TUMORI “REGINA ELENA” Via Elio Chianesi, 53 00144 Roma Tel.+39 06 52662728-5330 Fax +39 06 52665523 e-mail: [email protected] www.ifo.it Center for Experimental Research Via delle Messi d’Oro, 156/158 00158 Roma Tel.+39 06 52662538 Fax +39 06 52662502 email: [email protected] www.ifo.it Intermedia editore Healthcare Communication Network via Malta 12B - 25124 Brescia Tel.030.226105 - Fax. 030.2420472 [email protected] Via C. Morin, 44 - 00195 Roma Tel.06.3723187 [email protected] www.medinews.it INDEX pag. 5 SCIENTIFIC DIRECTOR’S REPORT pag. 8 SCIENTIFIC ACTIVITY pag. 12 CLINICAL ACTIVITY pag. 17 DEPARTMENTS: SC, SSD pag. 19 SCIENTIFIC REPORTS pag. 191 PUBLICATIONS IN REFERENCED JOURNALS pag. 210 ABSTRACTS FROM PUBLICATIONS IN REFERENCED JOURNALS pag. 269 PUBLICATIONS IN NON-REFERENCED JOURNALS pag. 271 BOOKS - BOOK CHAPTERS pag. 273 ABSTRACTS:INTERNATIONAL CONGRESSES pag. 289 ABSTRACTS:NATIONAL CONGRESSES pag. 303 JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH pag. 304 HOSTED LECTURES pag. 306 INTRAMURAL SEMINARS C.R.S. pag. 308 MULTIDISCIPLINARY SEMINARY pag. 311 BREAKFAST MEETINGS pag. 314 ORGANIZATION OF SEMINARS AND MEETINGS pag. 317 CERTIFIED COURSES pag. 320 POST-GRADUATE SPECIALIZATION COURSES AND VENUES pag. 323 TEACHING COURSES pag. 325 OVERSEAS TRAINING AND EXPERIENCE pag. 326 PARTICIPATION TO DEFINITION OF GUIDELINES pag. 327 RESEARCH PROJECTS pag. 338 FELLOWSHIPS 3 pag. 339 CONSULTANTS pag. 340 RESEARCH CONTRACTS pag. 344 VISITING RESEARCHERS pag. 347 REVIEWING AND EDITORIAL BOARD MEMBERSHIP pag. 349 RESEARCH PROJECT REVIEW pag. 350 APPOINTMENTS TO FOUNDATIONS,SOCIETIES,ASSOCIATIONS pag. 354 AWARDS pag. 355 BILATERAL AGREEMENTS pag. 358 PROTOCOLS LIST ACCORDING TO PATHOLOGY APPROVED BY THE ETHIC COMMITTEE 4 SCIENTIFIC DIRECTOR’S REPORT Francesco Cognetti Scientific Director Professor Francesco Cognetti is currently the Scientific Director of the Regina Elena Cancer Research Institute in Rome. Professor Cognetti designed and conducted relevant clinical studies in 1980’s and 90’s in the field of the treatment of head and neck cancer leading to significant contribution in the devel- opment of combined treatments in localized disease and new drugs in the advanced or metastatic setting. He also conducted studies on supportive care in neoplastic patients mainly on control of emesis during chemotherapy. He is presently conducting large scale controlled clinical trials on adjuvant chemotherapy in operable breast cancer as chairman of the GIM (Gruppo Italiano Mammella), which is the unique national cooperative group for clinical research on breast cancer. He obtained a Master’s degree in Medicine and Surgery in 1975, and went on to specialize in Internal Medicine in 1981.Then from 1984,he followed a career in Oncology,and gained European Certification in Medical Oncology in London in 1989. Professor Cognetti is a member of several international organizations such as ESMO (the European Society for Medical Oncology) where he was Chairman of the Membership Com- mittee. He was a member of the Executive Board and the Steering Committee and is the na- tional representative for Italy, as well as being an active member of the Head and Neck Co- operative Group of EORTC (the European Organization for Research and Treatment of Cancer), where he was secretary. He also represents Italy through his involvement in several prestigious organizations includ- ing AIOM (the Italian Association of Medical Oncology) where he was President until Oc- tober 2003, as Secretary and Treasurer of the Italian Alliance against Cancer Association, as an elected member of the Italian Health Governing Council and as a member of the Italy- USA Executive Committee for Research in Oncology. He is also member of the National Committee for Oncology, appointed by the Minister of Health. Professor Cognetti is the author and co-author of more than 200 publications. He is also a Peer Reviewer of the Annals of Oncology, the official journal of the European Society for Medical Oncology. Staff: Secretariat: FEDERICA CERVINI SANDRO GENOVESI SILVIA MALVEZZI CARMELA MATRASCIA GIOVANNA SANTUCCIO ANTONIO DE PAOLIS Fund raising office: ANNE SONIA CONVERS International Affairs Bureau: ILARIA VALLATI 5 Research Administration Office (Unità amministrativa per la ricerca - S.A.R.): TOMMASO COPPOLA - Director PIERA BRUGNOLI SABRINA DEL PESCO MARIA LA ROSA DORIANA SALVATI Education (CME) and Training, Congress Center Management: EUGENIO POGGI CAROL SCIOSCIA SABRINA SORESI Data Center for Clinical Trials: DIANA GIANNARELLI - Director FEDERICA FALCIONI BARBARA MATRASCIA - Contracted staff MARIO PELLICCIOTTA - Contracted staff ISABELLA SPERDUTI - Contracted staff Office for the Management of the Regional clinical and scientific activity: ITALO LORENZON Library, scientific information and documentation: GAETANA COGNETTI - Director EMANUELA DIMIZIANI - Director GIOVANNI CAVALLOTTI GIUSEPPE FILARDO ANTONIO VERBICARO Photographers - Tecnical Service: IVANA ZARDIN MAURO DI GIOVANNI During the year 2004 there was a significant general increase of the clinical activity, with about 14,000 hospitalizations and 869,000 outpatient services, thus allowing an important growth of the clinical trials (186 running in the year and the total number of patients enrolled for the same trials equals to 1763).The Institute reached, therefore, a 2nd national position among the centers and facilities involved into clinical trials as scored by the periodic report pro- duced by the Minister of Health.At the same time, we had an increase of the clinical trials coordinated by the Institute and the number of the no-profit studies in comparison to those sponsored by the pharmaceutical companies. Of considerable relevance the contribution given by the Institute in the role of the coordinating center to the GIM Cooperative Group (Gruppo Italiano Mammella) in conducting clinical trials in adjuvant setting in breast cancer and to a national cooperative group on adjuvant chemotherapy in bladder carcinoma.The Institute run trials on about twenty new antitumoral agents.As in previous years we have been successful in 2004 in obtaining grant support from many different sources: out of a grand total of 9.701.637, where 6.715.470 from the Ministry of Health (significantly decreased on a national basis of a funding for both Current and Targeted Research) when compared with pre- vious years; 1.350.000 from AIRC and FIRC; 1.231.867 from the European Community and 404.300 from other sources.The Institute published a total number of 171 scientific papers for a rough impact factor equals to 656.9. In December 2004 we had a site visit of a committee of scientists and directors of the Ministry of Health which confirmed our recognition as National Scientific Institute.The clinical activity was reorganized through the establishing of the Disease Management Team – DMT – working groups for single tumors, in total 21, aiming at the formulation of diagnostic and therapeutic guidelines, the discussion of clinical cases,the planning of research activities and the standardization of clinical trials pro- 6 tocols among the different services and divisions, also in cooperation with other institutions or cooperative groups.The DMT groups started to meet regularly every week to discuss clinical cases, and research issues for the single neoplastic pathologies.The international scientific coop- eration with foreign countries started with the aim to support the exchange of experiences in the specific fields of education, exchange of researchers and professors, organizations of semi- nars and bilateral workshops and have already started with Tunisia, Israel and China.The educational and training activity has had a significant increase with 117 intramural events (breakfast-meetings, panels, lectures) organized for a total no.of 1085 credits, double the num- ber of the previous year. On a translational and experimental research’s point of view, the Institute, leading of a network, mainly of the city of Rome’s research institutions, won an AIRC competition for the oncogenomic technological platform (Rome Oncogenomic Center ROC) foreseeing the organization of a central CORE FACILITY of 700 square meters with 12 module labs including technologies of high complexity.The basic research Core Program is organized into three research work packages: a) integrated approaches for targeted gene identifications; b) MI-RNA and diagnostic and therapeutic tools to fight cancer; c) can- cer and cancer stem-cells.The Institute was also awarded as coordinating center a EC fund- ing within the VI Framework Research Program for a cooperative international research study on P53 protein in which other 20 important European research Institutions are partecipat- ing. The Research activity of the Experimental Oncology Department has mainly been focused on new molecular indicators useful in the diagnosis and prevention for tumors, on pre- clinical approaches to best new drugs, on the genetics of tumors, immunotherapy, vaccines and gene therapy.The use of animal models (transgenic mice and nude mice with human tumor transplants) has permitted the production of specific antibodies for functional domains of onco- proteins.An integrated database system (Tissue and Serum Bank, Clinical Data) was creat- ed with the aim to define a proper and clear pattern